Literature DB >> 3082600

Efficacy of glycoprotein inhibitors alone and in combination with trifluridine in the treatment of murine herpetic keratitis.

Y J Gordon, K P Cheng, T Araullo-Cruz, E Romanowski, B J Johnson, H A Blough.   

Abstract

The present study examined the anti-herpetic effect of the glycoprotein inhibitors, hydroxynorvaline and 2-deoxyglucose, alone and in combination with trifluridine on murine ocular herpes. Following ocular inoculation with a large dose of HSV-1 RE strain (10(6) pfu), ICR mice were treated during the acute infection with different therapeutic regimens, and their efficacy was evaluated by ocular virus titers, clinical grading of blepharo-conjunctivitis and histological evaluation of stromal keratitis and iridocyclitis. The results following a large dose HSV-1 inoculum demonstrated that trifluridine was the best single therapeutic agent. Hydroxynorvaline and 2-deoxyglucose had no effect at all. Combination therapy of the glycoprotein inhibitors with trifluridine was no better than trifluridine alone. The mouse HSV-1 keratitis model proved to be an effective, economical alternative to the rabbit model for the evaluation of new antiviral agents.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3082600     DOI: 10.3109/02713688609015097

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  3 in total

1.  Herpes simplex virus type 1 corneal infection results in periocular disease by zosteriform spread.

Authors:  B C Summers; T P Margolis; D A Leib
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 2.  Role of Herpes Simplex Virus Type 1 (HSV-1) Glycoprotein K (gK) Pathogenic CD8+ T Cells in Exacerbation of Eye Disease.

Authors:  Ujjaldeep Jaggi; Shaohui Wang; Kati Tormanen; Harry Matundan; Alexander V Ljubimov; Homayon Ghiasi
Journal:  Front Immunol       Date:  2018-12-07       Impact factor: 7.561

Review 3.  Inhibitors of protein glycosylation and glycoprotein processing in viral systems.

Authors:  R Datema; S Olofsson; P A Romero
Journal:  Pharmacol Ther       Date:  1987       Impact factor: 12.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.